OVID Stock — Ovid Therapeutics Inc.: Cash, EV, Pipeline

Share price

$2.69

Market cap

$525.4M

Cash

$117.2M

Enterprise value

$408.2M

Balance sheet

Cash	$117.2M
Debt	$0.0M
Net cash	$117.2M
Enterprise value	$408.2M
Basic shares	184.8M shares
Fully diluted shares	268.0M shares
Fully diluted market cap	$720.8M
Cash per share	$0.63

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading OVID daily closes…

Loading price history…

Pipeline assets

OV329

Phase 1 · Active Modality: small molecule (oral)

Target GABA-aminotransferase (GABA-AT)

Partnerships Northwestern University: exclusive worldwide license; milestones up to $5.3M + low-to-mid single-digit royalties.

Indications

Epilepsy/seizures (Phase 1)
Tuberous sclerosis complex (TSC) (Stage not disclosed)
Infantile spasms (IS) (Stage not disclosed)

Status note Next-generation GABA-AT inhibitor (10-K fallback for target/modality). Phase 1 in healthy subjects completed; regulatory discussions underway for planned Phase 2 patient studies. Additive studies launching to expand into TSC and IS.

OV4071

Stage not disclosed · Active Modality: small molecule

Target KCC2

Status note KCC2 direct activator program (target/modality per 10-K fallback). First IND/CTA (or foreign equivalent) cleared (announced prior to Apr 2026 warrant expiry). No indication stated.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	7,417,479	+2,873,366	0.94%	2026-08-14
Braidwell LP	5,919,464	+5,919,464	0.59%	2026-08-14
Ikarian Capital	2,269,704	-625,000	1.00%	2026-08-14
Sphera Biotech	1,353,000	-269,828	0.52%	2026-08-14
OrbiMed Advisors	747,000	+747,000	0.04%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

OVID — Ovid Therapeutics Inc.

Balance sheet

Price history

Pipeline assets

Institutional holders